CN114502187A - 一种肽酰胺类组合物及其制备 - Google Patents

一种肽酰胺类组合物及其制备 Download PDF

Info

Publication number
CN114502187A
CN114502187A CN202080058211.4A CN202080058211A CN114502187A CN 114502187 A CN114502187 A CN 114502187A CN 202080058211 A CN202080058211 A CN 202080058211A CN 114502187 A CN114502187 A CN 114502187A
Authority
CN
China
Prior art keywords
alkyl
injection
compound
radical
carbocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080058211.4A
Other languages
English (en)
Other versions
CN114502187B (zh
Inventor
莫毅
李洪湖
张李
马香玲
赵璨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tibet Haisike Pharmaceutical Co ltd
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Liaoning Haisco Pharmaceutical Co Ltd
Haisco Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd, Liaoning Haisco Pharmaceutical Co Ltd, Haisco Pharmaceutical Group Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Publication of CN114502187A publication Critical patent/CN114502187A/zh
Application granted granted Critical
Publication of CN114502187B publication Critical patent/CN114502187B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明公开一种肽酰胺类化合物组合物及其制备方法，及其医药上的用途，具体为含有式(I)结构化合物及pH调节剂，溶液pH值为3～5.5。组合物稳定、辅料种类少，临床使用稳定。
Figure DDA0003508317140000011

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN202080058211.4A 2019-08-23 2020-08-24 一种肽酰胺类组合物及其制备 Active CN114502187B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019107517007 2019-08-23
CN201910751700 2019-08-23
PCT/CN2020/110760 WO2021036975A1 (zh) 2019-08-23 2020-08-24 一种肽酰胺类组合物及其制备

Publications (2)

Publication Number Publication Date
CN114502187A true CN114502187A (zh) 2022-05-13
CN114502187B CN114502187B (zh) 2024-06-25

Family

ID=74683763

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080058211.4A Active CN114502187B (zh) 2019-08-23 2020-08-24 一种肽酰胺类组合物及其制备

Country Status (11)

Country Link
US (1) US20220305074A1 (zh)
EP (1) EP4019033A4 (zh)
JP (1) JP7571123B2 (zh)
KR (1) KR20220069000A (zh)
CN (1) CN114502187B (zh)
AU (1) AU2020338767A1 (zh)
BR (1) BR112022003359A2 (zh)
CA (1) CA3152065A1 (zh)
MX (1) MX2022002187A (zh)
TW (1) TWI764248B (zh)
WO (1) WO2021036975A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240207353A1 (en) * 2021-04-12 2024-06-27 Xizang Haisco Pharmaceutical Co., Ltd. Use of peptide amide compound in preparation of drug for treating pruritus

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1666741A (zh) * 2004-03-10 2005-09-14 山东绿叶制药股份有限公司 稳定的纳洛酮冻干粉针剂及其制备工艺
CN1895251A (zh) * 2005-07-13 2007-01-17 汕头大学医学院 稳定的盐酸纳美芬注射液及其制备方法
US7402564B1 (en) * 2006-11-10 2008-07-22 Cara Therapeutics, Inc. Synthetic peptide amides
WO2019015644A1 (zh) * 2017-07-21 2019-01-24 四川海思科制药有限公司 肽酰胺类化合物及其制备方法和在医药上的用途
CN109280075A (zh) * 2017-07-21 2019-01-29 四川海思科制药有限公司 肽酰胺类化合物及其制备方法和在医药上的用途
CN109280076A (zh) * 2017-07-21 2019-01-29 四川海思科制药有限公司 肽酰胺类化合物及其制备方法和在医药上的用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1666741A (zh) * 2004-03-10 2005-09-14 山东绿叶制药股份有限公司 稳定的纳洛酮冻干粉针剂及其制备工艺
CN1895251A (zh) * 2005-07-13 2007-01-17 汕头大学医学院 稳定的盐酸纳美芬注射液及其制备方法
US7402564B1 (en) * 2006-11-10 2008-07-22 Cara Therapeutics, Inc. Synthetic peptide amides
CN101627049A (zh) * 2006-11-10 2010-01-13 卡拉治疗学股份有限公司 合成酞酰胺
WO2019015644A1 (zh) * 2017-07-21 2019-01-24 四川海思科制药有限公司 肽酰胺类化合物及其制备方法和在医药上的用途
CN109280075A (zh) * 2017-07-21 2019-01-29 四川海思科制药有限公司 肽酰胺类化合物及其制备方法和在医药上的用途
CN109280076A (zh) * 2017-07-21 2019-01-29 四川海思科制药有限公司 肽酰胺类化合物及其制备方法和在医药上的用途

Also Published As

Publication number Publication date
KR20220069000A (ko) 2022-05-26
EP4019033A4 (en) 2022-12-14
JP7571123B2 (ja) 2024-10-22
EP4019033A1 (en) 2022-06-29
TW202114727A (zh) 2021-04-16
JP2022552065A (ja) 2022-12-15
WO2021036975A1 (zh) 2021-03-04
CA3152065A1 (en) 2021-03-04
US20220305074A1 (en) 2022-09-29
TWI764248B (zh) 2022-05-11
BR112022003359A2 (pt) 2022-05-17
AU2020338767A1 (en) 2022-03-31
CN114502187B (zh) 2024-06-25
MX2022002187A (es) 2022-03-11

Similar Documents

Publication Publication Date Title
KR101188691B1 (ko) 엑티나시딘 및 디사카라이드를 포함하는 제제
KR100911091B1 (ko) 항체의 안정화 방법 및 안정화된 용액상 항체 제제
EA032119B1 (ru) Композиции, содержащие бензодиазепины короткого действия
EP2618814B1 (en) Caspofungin composition
CN105434373B (zh) 一种注射用奥拉西坦冻干制剂及其制备方法
CN104042572B (zh) 一种含福沙匹坦二甲葡胺的注射用组合物及其制备方法
WO2013117969A1 (en) Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
CN113956269A (zh) 用于抑制蛋白激酶活性的二(杂)芳基大环化合物
AU2017422167A1 (en) Preparation of Pulsatilla saponin B4 for injection
EP4188544A1 (en) Anti-connexin antibody formulations
CN114502187A (zh) 一种肽酰胺类组合物及其制备
CA2563443A1 (en) Therapeutic formulations of desoxyepothilones
CN105213330A (zh) 一种帕瑞昔布钠冻干制剂及其制备方法
CN108350457B (zh) 稳定地含有抑制TGF-β1基因的表达的单链核酸分子的组合物
CN112175029A (zh) 抗真菌的大环多烯类新化合物
EP3040067A1 (en) Chlorogenic acid powder-injection and preparation method thereof
AU2013366718A1 (en) Novel crystalline forms of ceftaroline fosamil
CN115025205A (zh) 一种肽酰胺类注射液药物组合物及其制备方法和用途
EA044808B1 (ru) Композиция на основе амида с пептидной связью и способ ее получения
US9308174B2 (en) Lyophilized formulations of bendamustine hydrochloride
CN112694414A (zh) 一类取代苯酚羟基酸酯含n衍生物、制备和用途
JP2022500350A (ja) 安定したアザシチジン含有医薬組成物の製造方法
US20230381222A1 (en) Lyophilized pharmaceutical compositions of copper histidinate
CN104825438A (zh) 治疗消化系统疾病的药物盐酸雷尼替丁冻干粉针剂组合物
CN105434453B (zh) 一种注射用克林霉素磷酸酯药物组合物及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40064796

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20231225

Address after: 856099 Xingfu Jiayuan Economic Development Zone, Gyerba, Nedong District, Shannan City, Tibet Autonomous Region

Applicant after: Tibet Haisike Pharmaceutical Co.,Ltd.

Address before: 611130 Sichuan Chengdu Wenjiang District Science and Technology Park cross strait Bailey Road 136

Applicant before: SICHUAN HAISCO PHARMACEUTICAL Co.,Ltd.

Applicant before: LIAONING HAISCO PHARMACEUTICAL Co.,Ltd.

Applicant before: HAISCO PHARMACEUTICAL Group Inc.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant